FindMyKOL
Clinical trialNCT03121092TerminatedInterventional

ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients

NCT03121092 is an interventional trial sponsored by State University of New York - Downstate Medical Center. As of 18 Nov 2026, it was terminated. It studies ACEI or ARB in Hypertension and Hypotension. The registry lists an enrollment of 188 participants at 1 site in 1 country. The registry lists a start date of 16 May 2012 and a primary completion date of 7 Mar 2017.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03121092
FieldValue
Registry IDNCT03121092
StatusTerminated
Study typeInterventional trial
Lead sponsorState University of New York - Downstate Medical Center
Enrollment188
Registered sites1
Countries1
ConditionsHypertension and Hypotension
DrugsACEI or ARB
Start16 May 2012
Primary completion7 Mar 2017
Study completion7 Mar 2017
Last update posted19 Apr 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) are commonly used anti-hypertensive medications that may have implications on the management of a patient undergoing surgery. Limited research has looked at the effects of these medications on perioperative complications and mortality. Some studies conducted on small groups of inpatients with advanced vascular disease undergoing vascular surgery or coronary artery bypass grafting (CABG), suggest exacerbation of hypotension (low blood pressure) in patients who continued taking ACEI's or ARB's on the morning of their procedure. In addition, cases of low blood pressure (BP) that were refractory to standard treatment were reported. One recent retrospective study reported no difference in severe hypotension and only a modest difference in moderate hypotension managed by conventional treatment, but did not adequately address the risk of preoperative hypertension. A study recently published by the investigators (Twersky et al., 2014) in over 600 patients demonstrated no difference in preoperative hypertension in ambulatory surgery and same day admission patients. There has been limited data stratifying the degree of low BP based on severity but these were not done in ambulatory patients, and neither was the degree of high BP from discontinuing these medications addressed. As such, no uniform consensus has been reached and clinicians are unclear as to whether the reported inpatient findings are applicable to the outpatients, since they differ in many respects. The investigators propose to evaluate whether ACEI's and ARB's discontinued preoperatively have a negative impact on perioperative hemodynamics and patient outcome in a group of ambulatory and same day surgical patients. Similar to studies done on inpatients, the investigators will also evaluate patients receiving a standardized general anesthetic for hemodynamics following induction of anesthesia until surgical incision. The investigators hypothesize that continuing ACEI's and ARB's in the preoperative period does not result in an increased risk of severe hypotension (low blood pressure) following induction of general anesthesia.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Ketan Shevde, MD

    State University of New York - Downstate Medical Center

    Principal Investigator
  • Rebecca Twersky, MD, MPH

    Memorial Sloan Kettering Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Suny Downstate Medical Center

    Brooklyn

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ACEI or ARB
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03121092

Each answer restates registry values shown on this page.

What is NCT03121092?

NCT03121092 is an interventional trial sponsored by State University of New York - Downstate Medical Center. It studies ACEI or ARB in Hypertension and Hypotension.

Who leads NCT03121092?

The registry names Ketan Shevde, MD (principal investigator, State University of New York - Downstate Medical Center) and Rebecca Twersky, MD, MPH (principal investigator, Memorial Sloan Kettering Cancer Center) as overall officials.

Where does NCT03121092 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03121092 study?

The registered drug and biological interventions are ACEI or ARB.

When did NCT03121092 end?

The registry lists a primary completion date of 7 Mar 2017 and a study completion date of 7 Mar 2017. The sponsor last updated the record on 19 Apr 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.